Schedule 13G ownership disclosure

C4 Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 12529R107

Event date: 2025-10-17

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Bain Capital Life Sciences Fund II, L.P.

    Shares: 991,188 · Class: 1.07%

  • BCIP Life Sciences Associates, LP

    Shares: 120,722 · Class: 0.13%

  • BCLS II Equity Opportunities, LP

    Shares: 6,060,000 · Class: 6.25%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950130-25-000220
Form type
SCHEDULE 13G
Filer
Bain Capital Life Sciences Fund II, L.P.
CIK
CIK 1773187
Filed
Oct 24, 2025
Reporting period
Oct 17, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub